| Form | Liquid |
|---|
| Host Species | Humanized |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG4-nd |
|---|
| Purity | >95% as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1 mg/ml |
|---|
| Endotoxin Level | Please contact with the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | Complement receptor C3 subunit beta, Cell surface adhesion glycoproteins LFA-1/CR3/p150, 95 subunit beta, Integrin beta-2, MFI7, CD18, ITGB2, CD11A, Leukocyte function-associated molecule 1 alpha chai |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | P05107, P20701, P11215 |
|---|
| Background | Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.
|
|---|
| Alternative Names | Bispecific, Hu23F2G, 23F2G, 339086-79-2 |
|---|
| Species | Human |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|